NKTR—I looked at past PIVOT-02 data presentations again, this increase of CRs over time has been seen only in melanoma as far as I can tell, not shown in UC yet, NSCLC fizzled completely, and surprisingly no update from RCC since ASCO2018! And not surprisingly new dose escalation…come from NSCLC and RCC.
So, what’s your overall assessment of the bempeg program? I described it as “colossally chaotic” in a recent tweet (#msg-153385124).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”